Model Type: Rodent

  • Biodistribution in rodent and non-human primate

    Biodistribution Overview The biodistribution services that Atuka offers include evaluation of the distribution of viral vectors, small molecules, antibodies and other biologics, PET tracers, cells, exosomes and antisense oligonucleotides. Additional Test Items can be provided on a case-by-case basis depending upon the clients needs.  Administration of Test Items Atuka has the ability to administer Test…

  • PFF α-synuclein over-expressing rodent

    Model Overview Mouse aSyn PFFs are injected bilaterally into the striatum of rats or mice using stereotaxic techniques.Accumulations of pSer129-aSyn can be seen over the course of 30-, 60-, and 120-days allowing test compounds to be evaluated for their ability to prevent uptake of PFFs and the formation of pathologic forms of aSyn.  pSer129-aSyn-ir Deposits of…

  • Bilateral AAV α-synuclein over-expressing rodent

    Model Overview AAV1/2-hA53T-α-synuclein vectors are injected bilaterally into the substantia nigra of rats or mice using stereotaxic techniques. Degeneration of dopaminergic neurons occurs over several weeks allowing test compounds to be evaluated for disease modifying potential.  Tissue from one hemisphere can be fixed to allow counting of TH+ve cells in the substantia nigra and pSer129 aSyn pathology assessment in…

  • AAV α-synuclein over-expressing rodent

    Model Overview AAV1/2-hA53T-α-synuclein vectors are injected unilaterally into the substantia nigra of rats or mice using stereotaxic techniques. Degeneration of dopaminergic neurons occurs over several weeks allowing test compounds to be evaluated for disease modifying potential. Robust loss on dopaminergic endpoints Dopaminergic cell loss develops over time so that at 6 weeks post-surgery there is…

  • Bilateral 6-OHDA-lesioned rodent

    Model Overview Rats or mice, receive bilateral injections of 6-OHDA directly into the striatum resulting in ‘partial’ loss of dopaminergic innervation and subsequent abnormal motor behaviours. Motor deficits can be quantified using the Open Field Arena and dose dependently reversed via administration of L-DOPA. The bilateral 6-OHDA lesioned rodent is therefore an ideal model in…

  • Unilateral 6-OHDA-lesioned rodent models of dyskinesia

    Model Overview Rats or mice, previously made hemi-parkinsonian with 6-OHDA are administered L-DOPA (10-15 mg/kg, q.d.) for a period of 2-3 weeks until the development of AIMs. Once established, dyskinesia is robust and stable upon repeat L-DOPA challenge and can be maintained over several months allowing test compounds to be thoroughly evaluated in the same…

  • MPTP-lesioned mouse

    Model Overview Various iterations of the MPTP-lesioned mouse are offered by Atuka. In our most commonly used model, MPTP (25 mg/kg, i.p.) is administered to C57bl/6 mice once daily for 5 days. This leads to a loss of tyrosine hydroxylase positive neurons in the substantia nigra that is stable over a period of weeks. Test…